Although the trial was conducted on melanoma patients, two of the RNA-LPX vaccines tested encoded MAGE-A3 and NY-ESO-1, respectively, which are also expressed in HNSCC. This evidence concerns the gene MAGEA3 and head and neck squamous cell carcinoma.